168 related articles for article (PubMed ID: 12865442)
1. Prostate cancer prevention trial yields positive results, but with a few cautions.
Reynolds T
J Natl Cancer Inst; 2003 Jul; 95(14):1030-1. PubMed ID: 12865442
[No Abstract] [Full Text] [Related]
2. Stat bite: Estimated effect of finasteride on prostate cancer development.
J Natl Cancer Inst; 2003 Jul; 95(14):1031. PubMed ID: 12865443
[No Abstract] [Full Text] [Related]
3. The prevention of prostate cancer--the dilemma continues.
Scardino PT
N Engl J Med; 2003 Jul; 349(3):297-9. PubMed ID: 12824458
[No Abstract] [Full Text] [Related]
4. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
5. Hormonal prevention of prostate cancer.
Brawley OW
Urol Oncol; 2003; 21(1):67-72. PubMed ID: 12684130
[TBL] [Abstract][Full Text] [Related]
6. Finasteride for chemoprevention of prostate cancer: why has it not been embraced?
de Vere White RW
J Clin Oncol; 2007 Jul; 25(21):2999-3000. PubMed ID: 17634478
[No Abstract] [Full Text] [Related]
7. Male breast cancer during finasteride therapy.
Lee SC; Ellis RJ
J Natl Cancer Inst; 2004 Feb; 96(4):338-9. PubMed ID: 14970289
[No Abstract] [Full Text] [Related]
8. Chemoprevention of prostate cancer with finasteride.
Thompson I; Feigl P; Coltman C
Important Adv Oncol; 1995; ():57-76. PubMed ID: 7672814
[No Abstract] [Full Text] [Related]
9. Benign prostatic hypertrophy: update on drug therapy.
Tejani A; Musini V; Perry TL; Mintzes B; Wright JM
Can Fam Physician; 2006 Sep; 52(9):1075-6, 1077-8. PubMed ID: 17279217
[No Abstract] [Full Text] [Related]
10. Effect of finasteride on risk of prostate cancer: how little we really know.
Rubin MA; Kantoff PW
J Cell Biochem; 2004 Feb; 91(3):478-82. PubMed ID: 14755678
[TBL] [Abstract][Full Text] [Related]
11. [Chemoprevention of prostate cancer. Current status].
Schmitz-Dräger BJ; Lümmen G; Schäfer RM
Urologe A; 2007 Jun; 46(6):611-5. PubMed ID: 17483928
[TBL] [Abstract][Full Text] [Related]
12. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
13. Finasteride for prevention of prostate cancer.
Med Lett Drugs Ther; 2008 Jun; 50(1289):49-50. PubMed ID: 18583946
[No Abstract] [Full Text] [Related]
14. A big study yields big questions.
Zuger A
N Engl J Med; 2003 Jul; 349(3):213-4. PubMed ID: 12867605
[No Abstract] [Full Text] [Related]
15. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
16. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?
Andriole GL; Humphrey PA; Serfling RJ; Grubb RL
J Natl Cancer Inst; 2007 Sep; 99(18):1355-6. PubMed ID: 17848666
[No Abstract] [Full Text] [Related]
17. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
18. The Prostate Cancer Prevention Trial and the future of chemoprevention.
Thompson IM; Tangen CM; Lucia MS
BJU Int; 2008 Apr; 101(8):933-4. PubMed ID: 18353157
[No Abstract] [Full Text] [Related]
19. The evolution of the PCPT from clinical to molecular analyses.
Hoque A
Nat Clin Pract Oncol; 2006 Nov; 3(11):581. PubMed ID: 17080169
[No Abstract] [Full Text] [Related]
20. High-grade prostate cancer and the prostate cancer prevention trial.
Logothetis CJ; Schellhammer PF
Cancer Prev Res (Phila); 2008 Aug; 1(3):151-2. PubMed ID: 19138948
[No Abstract] [Full Text] [Related]
[Next] [New Search]
